Dijon, France, April 25, 2024 — Crossject (ISIN: FR0011716265; Euronext: ALCJ) is a specialty pharmaceutical company leveraging its proprietary needle-free auto-injector technology platform, ZENEO®, to develop products for emergency situations. reports its audited financial results for the year ended December 31, 2023. These results are now available on our website.
Key financial information as of December 31, 2023
Crossject's financial results for the year ending 31 December 2023 have been fully audited and have a minor change of €0.17 million compared to the previous report released on 29 March and available here. Changes have been made.
All 2023 financial reports will be available for viewing on the Crossject website from April 30th and will also be published in the Appendix below.
The table below summarizes our income statements for the years ended December 31, 2023 and 2022.
|
thousand euros, as of December 31st |
2023 |
2022 |
|
Operating income |
12 826 |
9 718 |
|
Operating expenses |
-24 626 |
-23 005 |
|
Purchase of raw materials and consumables |
-1 595 |
-498 |
|
Other purchases and external expenses |
-8 869 |
-8 116 |
|
personal expenses |
-7 713 |
-7 424 |
|
taxes and duties |
-267 |
-176 |
|
Depreciation, amortization and reserves |
-5 688 |
-6 358 |
|
Other costs |
-494 |
-433 |
|
Operating profit and loss |
-11,800 |
-13 288 |
|
Financial income/expenses |
-497 |
-319 |
|
Extraordinary income/expenses |
791 |
228 |
|
Corporate tax |
2 867 |
2 222 |
|
Net profit or loss |
-8 638 |
-11 157 |
About Crossject
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharmaceutical company developing emergency products utilizing its proprietary needle-free auto-injector technology, ZENEO. The company is in advanced regulatory development of his ZEPIZURE®, an epilepsy relief therapy, and he has a $60 million contract with the Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the company's award-winning needleless auto-injector ZENEO®, which allows patients and untrained caregivers to easily and instantly administer emergency medications by intramuscular injection, even through bare skin or over clothing. Designed to be administered. Other products the company is developing include rescue treatments for allergic shock, adrenal insufficiency, opioid overdose and asthma attacks.
For more information, please contact us below.
|
Investor |
media |
appendix
|
Income statement (K€) |
2023/12/31 |
2022/12/31 |
change |
|
revenue |
145 |
954 |
-809 |
|
storage production |
591 |
348 |
243 |
|
capital production |
3 594 |
6 104 |
-2 510 |
|
Subsidy |
133 |
Five |
128 |
|
Reversal of reserves and transfer of expenses |
2 632 |
445 |
2 187 |
|
Other income/income |
6 231 |
1 861 |
4 370 |
|
Operating income |
13 326 |
9 717 |
3 609 |
|
Purchasing raw materials and other consumables |
1 625 |
1002 |
623 |
|
Inventory trends (raw materials and other supplies) |
-29 |
-505 |
476 |
|
Other purchases and external expenses |
8 869 |
8 115 |
754 |
|
taxes and duties |
267 |
177 |
90 |
|
personnel costs |
7 714 |
7 425 |
289 |
|
Depreciation and amortization expenses |
4 504 |
5 263 |
-759 |
|
Other provisions |
1 682 |
1 095 |
587 |
|
Other costs |
494 |
433 |
61 |
|
Operating expenses |
25 126 |
23 005 |
2 121 |
|
Operating profit and loss |
-11,800 |
-13 288 |
1 488 |
|
Financial income/expenses |
-497 |
-319 |
-178 |
|
Extraordinary income/expenses |
791 |
228 |
563 |
|
research tax credit |
2 867 |
2 222 |
645 |
|
Net profit or loss |
-8 638 |
-11 157 |
2 519 |
|
Balance sheet – Liabilities (in k€) |
2023/12/31 |
2022/12/31 |
change |
|
Capito Propre |
|||
|
capital |
3 676 |
3 652 |
twenty four |
|
capital surplus |
785 |
18 312 |
-17 527 |
|
retained earnings |
-1 757 |
-8 786 |
7 029 |
|
Profit and loss for the period |
-8 638 |
-11 157 |
2 519 |
|
investment subsidy |
665 |
665 |
0 |
|
Total stockholders' equity |
-5 269 |
2 686 |
-7 955 |
|
conditional advance |
7 060 |
7 476 |
-416 |
|
Prepare for contingencies and costs |
694 |
1 420 |
-726 |
|
loans and loans |
|||
|
bond |
18 |
355 |
-337 |
|
loan |
16 171 |
11 048 |
5 123 |
|
others |
2 732 |
2 722 |
Ten |
|
Liabilities – Trade payables |
4 323 |
3 523 |
800 |
|
Total tax and social security debt |
2 149 |
1 833 |
316 |
|
Liabilities against fixed assets |
82 |
1 764 |
-1 682 |
|
deferred income |
681 |
32 |
649 |
|
Total debt |
26 156 |
21 277 |
4 879 |
|
Total equity and debt |
28 641 |
32 859 |
-4 218 |
|
Balance Sheet – Assets (K€) |
2023/12/31 |
2022/12/31 |
change |
|
Fixed asset |
|||
|
Research and Development |
10 730 |
10 691 |
39 |
|
patents and trademarks |
0 |
0 |
0 |
|
Other intangible assets |
0 |
0 |
0 |
|
land |
14 |
89 |
-75 |
|
Tangible fixed assets |
2 736 |
5 085 |
-2 350 |
|
Assets under construction |
2 942 |
2 492 |
450 |
|
financial assets |
1 544 |
672 |
872 |
|
Total fixed assets |
17 966 |
19 029 |
-1 064 |
|
current assets |
|||
|
Raw materials and other consumables |
1 649 |
1 416 |
232,6 |
|
Work in progress |
1 485 |
588 |
897 |
|
Prepayments and prepayments received for orders in progress |
187 |
345 |
-158 |
|
Trade receivables and related receivables |
2 079 |
726 |
1353 |
|
State and other debts |
2 512 |
2 450 |
62 |
|
marketable securities |
0 |
0 |
0 |
|
available cash |
2 304 |
7 769 |
-5465 |
|
Prepaid/Deferred Expenses |
459 |
536 |
-76,6 |
|
Total current assets |
10 675 |
13 830 |
-3 155 |
|
Total assets |
28 641 |
32 859 |
-4 219 |
|
Balance sheet – Liabilities (in k€) |
2023/12/31 |
2022/12/31 |
change |
||||
|
Capito Propre |
|||||||
|
capital |
3 676 |
3 652 |
twenty four |
||||
|
capital surplus |
785 |
18 312 |
-17 527 |
||||
|
regulated reserves |
0 |
0 |
0 |
||||
|
retained earnings |
-1 757 |
-8 786 |
7 029 |
||||
|
Profit and loss for the period |
-8 638 |
-11 157 |
2 519 |
||||
|
investment subsidy |
665 |
665 |
0 |
||||
|
Total stockholders' equity |
-5 269 |
2 686 |
-7 955 |
||||
|
conditional advance |
7 060 |
7 476 |
-416 |
||||
|
Prepare for contingencies and costs |
694 |
1 420 |
-726 |
||||
|
loans and loans |
|||||||
|
bond |
18 |
355 |
-337 |
||||
|
loan |
16 171 |
11 048 |
5 123 |
||||
|
others |
2 732 |
2 722 |
Ten |
||||
|
Liabilities – Trade payables |
4 323 |
3 523 |
800 |
||||
|
Total tax and social security debt |
2 149 |
1 833 |
316 |
||||
|
Liabilities against fixed assets |
82 |
1 764 |
-1 682 |
||||
|
deferred income |
681 |
32 |
649 |
||||
|
Total debt |
26 156 |
21 277 |
4 879 |
||||
|
Total equity and debt |
28 641 |
32 859 |
-4 218 |
||||
|
Cash flow statement (K€) |
2023/12/31 |
2022/12/31 |
|||||
|
Net profit or loss |
– 8 638 |
– 11 157 |
|||||
|
Depreciation, amortization and reserves |
3 091 |
5 705 |
|||||
|
Capital gain on sale (after tax) |
54 |
1 |
|||||
|
Calculating other income and expenses |
– 28 |
– 28 |
|||||
|
Operating cash flow |
-5 521 |
– 5 479 |
|||||
|
Changes in working capital requirements |
– 680 |
399 |
|||||
|
(1) Net cash generated/(used) by operating activities |
– 6 201 |
– 5,080 |
|||||
|
Acquisition of fixed assets |
– 6 403 |
– 6 778 |
|||||
|
Remove immobilization |
3 767 |
0 |
|||||
|
(2) Net cash generated/(used) by investing activities |
– 2 636 |
– 6 778 |
|||||
|
capital increase |
13 |
4 089 |
|||||
|
exercise of warrant |
333 |
3 003 |
|||||
|
loan |
8 090 |
4,000 |
|||||
|
repayment of loans |
– 3 396 |
– 969 |
|||||
|
Liabilities against fixed assets |
– 1 682 |
– 483 |
|||||
|
(3) Net cash generated/(used) by financing activities |
3 358 |
9 640 |
|||||
|
Change in cash and cash equivalents (1)+(2)+(3) |
– 5 479 |
– 2 218 |
|||||
|
open cash position |
7 770 |
9 983 |
|||||
|
Closing cash position |
2 291 |
7 770 |
|||||
attachment
